Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00788112 · ClinicalTrials.gov registry record · Phase 1
Vorinostat in Treating Women With Ductal Carcinoma in Situ of the Breast
A Phase 1 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT00788112 is a Phase 1 study that has completed, run by University of California, San Francisco. The registered enrollment target is 17 participants.
The verdict
NCT00788112, a Phase 1 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
RATIONALE: Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This clinical trial is studying how well vorinostat works in treating women with ductal carcinoma in situ of the breast.
Interventions
- GENETIC protein expression analysis
- OTHER laboratory biomarker analysis
- DRUG vorinostat
- OTHER immunohistochemistry staining method
- PROCEDURE neoadjuvant therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2009-07 |
| Est. Completion | 2015-08-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00788112
The ClinicalTrials.gov registry entry for NCT00788112 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which protein expression analysis is the first listed.
NCT00788112 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00788112 about?
NCT00788112 is a clinical study titled "Vorinostat in Treating Women With Ductal Carcinoma in Situ of the Breast". RATIONALE: Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This clinical trial is studying how well vorinostat works in treating women with ductal carcinoma in situ of the breast.
What is the current status of trial NCT00788112?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2009-07. Estimated completion is 2015-08-11.
What interventions are being tested in trial NCT00788112?
The interventions under investigation include: protein expression analysis (GENETIC), laboratory biomarker analysis (OTHER), vorinostat (DRUG), immunohistochemistry staining method (OTHER), neoadjuvant therapy (PROCEDURE).
Who is sponsoring clinical trial NCT00788112?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.